But in your scenario, AMRN is getting nothing. If REDUCE-IT stopped early, your theory is that AMRN promotes REDUCE-IT and the FDA then approves REDUCE-IT in the meantime. This is nothing extra. AMRN has the PI, and they could have went for the final judgment by now, so they could already promote REDUCE-IT via the PI or final judgement. So nothing extra there. And if REDUCE-IT is stopped early, results would have to be great, so the FDA would presumably approve REDUCE-IT regardless of whether they settle or not. So nothing extra there. So what exactly is AMRN getting extra that they wouldn't have gotten if they didn't drop the 1A case?
News 
Market Data 
Discover 
AI
